|
DE19608753C1
(de)
*
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
EP1623017B1
(en)
*
|
2003-05-08 |
2010-09-15 |
Life Technologies Corporation |
Generation and isolation of antigen-specific t cells
|
|
US20070032570A1
(en)
*
|
2003-11-11 |
2007-02-08 |
Canon Kabushiki Kaisha |
Ink comprising a block copolymer dispersing agent having a hydrophilic and a hydrophobic segment and an ink-applying process and apparatus using the same
|
|
AU2005287393A1
(en)
*
|
2004-06-18 |
2006-03-30 |
The University Of Montana |
AAV mediated gene delivery to cochlear cells
|
|
US20100080784A1
(en)
*
|
2008-09-12 |
2010-04-01 |
Torrey Pines Institute For Molecular Studies |
Methods for treating cachexia and lymphopenia
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
CN106459917B
(zh)
|
2014-04-23 |
2021-03-09 |
朱诺治疗学股份有限公司 |
分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
|
|
KR20170032406A
(ko)
|
2014-07-15 |
2017-03-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 조작된 세포
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
SG11201703203RA
(en)
|
2014-10-20 |
2017-05-30 |
Juno Therapeutics Inc |
Methods and compositions for dosing in adoptive cell therapy
|
|
HUE050264T2
(hu)
|
2014-11-05 |
2020-11-30 |
Juno Therapeutics Inc |
Eljárások transzdukálásra és sejtfeldolgozásra
|
|
JP7068820B2
(ja)
|
2014-12-03 |
2022-05-17 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法のための方法および組成物
|
|
TWI718118B
(zh)
|
2015-01-16 |
2021-02-11 |
美商奇諾治療有限公司 |
針對ｒｏｒ１之特異性抗體及嵌合抗原受體
|
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
US20180161368A1
(en)
|
2015-05-29 |
2018-06-14 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
|
WO2017095967A2
(en)
|
2015-11-30 |
2017-06-08 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
EP4212166A1
(en)
|
2015-12-03 |
2023-07-19 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against cell therapies
|
|
AU2016363025B2
(en)
|
2015-12-03 |
2021-04-08 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
|
ES2901795T3
(es)
|
2015-12-04 |
2022-03-23 |
Juno Therapeutics Inc |
Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular
|
|
EP3430549A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
|
MA43758A
(fr)
|
2016-03-16 |
2018-11-28 |
Yuan Ji |
Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
|
|
AU2017238218B2
(en)
|
2016-03-22 |
2024-05-02 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
US20190136230A1
(en)
|
2016-05-06 |
2019-05-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
EP3463401A4
(en)
|
2016-06-03 |
2020-01-22 |
Memorial Sloan Kettering Cancer Center |
ADOPTIVE CELL THERAPIES AS EARLY TREATMENT OPTIONS
|
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
|
CN110291402B
(zh)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
鉴定肽表位的方法、结合此类表位的分子和相关用途
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
CN110087672A
(zh)
|
2016-07-29 |
2019-08-02 |
朱诺治疗学股份有限公司 |
免疫调节多肽及相关组合物和方法
|
|
JP7062640B2
(ja)
|
2016-07-29 |
2022-05-06 |
ジュノー セラピューティクス インコーポレイテッド |
抗ｃｄ１９抗体に対する抗イディオタイプ抗体
|
|
AU2017322752A1
(en)
|
2016-09-12 |
2019-03-21 |
Juno Therapeutics, Inc. |
Perfusion bioreactor bag assemblies
|
|
JP2019529565A
(ja)
|
2016-09-28 |
2019-10-17 |
アトッサ・ジェネティックス・インコーポレイテッド |
養子細胞治療の方法
|
|
WO2018067618A1
(en)
|
2016-10-03 |
2018-04-12 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
|
CN110381963A
(zh)
|
2016-10-13 |
2019-10-25 |
朱诺治疗学股份有限公司 |
涉及色氨酸代谢途径调节剂的免疫治疗方法和组合物
|
|
EP3534938A2
(en)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
|
CA3040914A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
|
US11793833B2
(en)
|
2016-12-02 |
2023-10-24 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
|
BR112019011025A2
(pt)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
métodos para modulação de células t car
|
|
KR20190104528A
(ko)
|
2016-12-03 |
2019-09-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Car-t 세포들 투여를 결정하는 방법
|
|
JP2020511462A
(ja)
|
2016-12-03 |
2020-04-16 |
ジュノー セラピューティクス インコーポレイテッド |
キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
|
|
MX2019008538A
(es)
|
2017-01-20 |
2019-11-05 |
Juno Therapeutics Gmbh |
Conjugados de superficie celular y composiciones y métodos celulares relacionados.
|
|
WO2018151836A1
(en)
|
2017-02-17 |
2018-08-23 |
Fred Hutchinson Cancer Research Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
MX2019010171A
(es)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
|
|
KR102771581B1
(ko)
|
2017-03-14 |
2025-02-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
극저온 보관 방법
|
|
JOP20180027A1
(ar)
|
2017-03-28 |
2019-01-30 |
Cell Design Labs Inc |
بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
|
|
CN110730908B
(zh)
|
2017-04-07 |
2025-01-21 |
朱诺治疗学股份有限公司 |
表达前列腺特异性膜抗原（psma）或其修饰形式的工程化细胞及相关方法
|
|
EP3610261A1
(en)
|
2017-04-14 |
2020-02-19 |
Juno Therapeutics, Inc. |
Methods for assessing cell surface glycosylation
|
|
CN111032850B
(zh)
|
2017-04-27 |
2024-08-13 |
朱诺治疗学有限公司 |
寡聚粒子试剂及其使用方法
|
|
PT3618842T
(pt)
|
2017-05-01 |
2024-01-12 |
Juno Therapeutics Inc |
Combinação de uma terapia celular e de um composto imunomodulador
|
|
MX2019014268A
(es)
|
2017-06-02 |
2020-08-03 |
Juno Therapeutics Inc |
Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.
|
|
MX2019014288A
(es)
|
2017-06-02 |
2020-08-03 |
Juno Therapeutics Inc |
Articulos de manufactura y metodos relacionados a toxicidad asociada con terapia celular.
|
|
PL3538645T3
(pl)
|
2017-06-20 |
2021-11-08 |
Institut Curie |
Komórki odpornościowe z defektem suv39h1
|
|
US20220225597A1
(en)
|
2017-06-29 |
2022-07-21 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
|
KR20200064060A
(ko)
|
2017-07-29 |
2020-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 세포 증폭용 시약
|
|
ES2992909T3
(en)
|
2017-08-09 |
2024-12-19 |
Juno Therapeutics Inc |
Methods and compositions for preparing genetically engineered cells
|
|
MA49979A
(fr)
|
2017-08-09 |
2020-06-17 |
Juno Therapeutics Inc |
Procédés de production de compositions de cellules génétiquement modifiées et compositions associées
|
|
EP3676403A1
(en)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
|
WO2019051335A1
(en)
|
2017-09-07 |
2019-03-14 |
Juno Therapeutics, Inc. |
METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY
|
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
SG11202003862PA
(en)
|
2017-11-01 |
2020-05-28 |
Editas Medicine Inc |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
EP3704230B1
(en)
|
2017-11-01 |
2024-10-23 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
AU2018360801A1
(en)
|
2017-11-01 |
2020-05-14 |
Celgene Corporation |
Process for producing a T cell composition
|
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
PL3703750T3
(pl)
|
2017-11-01 |
2025-04-07 |
Juno Therapeutics, Inc. |
Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
|
|
CN111556893A
(zh)
|
2017-11-06 |
2020-08-18 |
爱迪塔斯医药股份有限公司 |
免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
|
|
MX2020004568A
(es)
|
2017-11-06 |
2020-10-05 |
Juno Therapeutics Inc |
Combinación de una terapia celular y un inhibidor de gamma secretasa.
|
|
MA50571A
(fr)
|
2017-11-10 |
2020-09-16 |
Juno Therapeutics Inc |
Réservoirs cryogéniques à système fermé
|
|
KR20200116081A
(ko)
|
2017-12-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포의 투약 및 조절 방법
|
|
CN112203680A
(zh)
|
2017-12-08 |
2021-01-08 |
朱诺治疗学股份有限公司 |
用于细胞疗法的表型标记和相关方法
|
|
KR102833956B1
(ko)
|
2017-12-08 |
2025-07-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포를 배양하기 위한 무혈청 배지 제형 및 이의 사용 방법
|
|
CN112004824B
(zh)
|
2017-12-08 |
2024-09-13 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
KR20200110745A
(ko)
|
2017-12-15 |
2020-09-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
|
|
WO2019126358A1
(en)
|
2017-12-22 |
2019-06-27 |
Cell Design Labs, Inc. |
Single- and multi-chain chimeric antigen receptors
|
|
CN111971059A
(zh)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
使用过继细胞疗法和检查点抑制剂的组合疗法
|
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
US12280119B2
(en)
|
2018-03-23 |
2025-04-22 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
CA3095084A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
BR112020019313A2
(pt)
|
2018-04-05 |
2021-01-05 |
Juno Therapeutics Inc |
Receptores de células t e células modificadas que expressam os mesmos
|
|
KR20210029707A
(ko)
|
2018-04-05 |
2021-03-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물
|
|
EP3787751A1
(en)
|
2018-05-03 |
2021-03-10 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
|
SG11202011751WA
(en)
|
2018-06-22 |
2021-01-28 |
Kite Pharma Inc |
Chimeric transmembrane proteins and uses thereof
|
|
CN113474450A
(zh)
|
2018-08-09 |
2021-10-01 |
朱诺治疗学股份有限公司 |
产生工程化细胞的方法以及所述工程化细胞的组合物
|
|
AU2019316647A1
(en)
|
2018-08-09 |
2021-02-25 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
|
US12366580B2
(en)
|
2018-09-11 |
2025-07-22 |
Juno Therapeutics, Inc. |
Methods for mass spectrometry analysis of engineered cell compositions
|
|
EP4420723A3
(en)
|
2018-10-12 |
2024-12-04 |
Theradaptive, Inc. |
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
|
|
EP3874024A1
(en)
|
2018-10-31 |
2021-09-08 |
Juno Therapeutics GmbH |
Methods for selection and stimulation of cells and apparatus for same
|
|
EP3873937A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
AU2019372331A1
(en)
|
2018-11-01 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
WO2020097132A1
(en)
|
2018-11-06 |
2020-05-14 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
US12263190B2
(en)
|
2018-11-08 |
2025-04-01 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
|
AU2019381827A1
(en)
|
2018-11-16 |
2021-06-10 |
Juno Therapeutics, Inc. |
Methods of dosing engineered T cells for the treatment of B cell malignancies
|
|
JP7695882B2
(ja)
|
2018-11-30 |
2025-06-19 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
|
BR112021010120A2
(pt)
|
2018-11-30 |
2021-08-31 |
Juno Therapeutics, Inc. |
Métodos para dosagem e tratamento de malignidades celulares em terapia celular adotiva
|
|
SG11202107976SA
(en)
|
2019-01-29 |
2021-08-30 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
JP7754722B2
(ja)
|
2019-05-01 |
2025-10-15 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたｃｄ２４７遺伝子座からキメラ受容体を発現する細胞、関連ポリヌクレオチド、および方法
|
|
MA55811A
(fr)
|
2019-05-01 |
2022-03-09 |
Editas Medicine Inc |
Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés
|
|
BR112021024404A2
(pt)
|
2019-06-07 |
2022-04-19 |
Juno Therapeutics Inc |
Cultura de célula t automatizada
|
|
AU2020293230A1
(en)
|
2019-06-12 |
2022-01-27 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
|
|
MX2021015451A
(es)
|
2019-06-21 |
2022-02-11 |
Kite Pharma Inc |
RECEPTORES DE TGF-ß Y MÉTODOS DE USO.
|
|
EP4003407A1
(en)
|
2019-07-23 |
2022-06-01 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
EP4017527A1
(en)
|
2019-08-22 |
2022-06-29 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
|
|
EP4022637A2
(en)
|
2019-08-30 |
2022-07-06 |
Juno Therapeutics, Inc. |
Machine learning methods for classifying cells
|
|
US20220333132A1
(en)
|
2019-09-03 |
2022-10-20 |
Sana Blotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
|
WO2021070956A1
(ja)
|
2019-10-11 |
2021-04-15 |
タカラバイオ株式会社 |
ｓｉＲＮＡ発現ベクター
|
|
WO2021084050A1
(en)
|
2019-10-30 |
2021-05-06 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
|
KR20220131892A
(ko)
|
2019-11-05 |
2022-09-29 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료용 ｔ 세포 조성물의 속성 결정 방법
|
|
BR112022007548A2
(pt)
|
2019-11-07 |
2022-07-12 |
Juno Therapeutics Inc |
Combinação de uma terapia de célula t e (s)-3-[4-(4-morfolin-4-ilmetil-benzilóxi)-1-oxo-1,3-di-hidro-isoindol-2-il]-piperidina-2,6-diona
|
|
MX2022006715A
(es)
|
2019-12-06 |
2022-09-23 |
Juno Therapeutics Inc |
Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
|
|
WO2021113776A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
|
EP4069742A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
|
EP4093433A1
(en)
|
2020-01-24 |
2022-11-30 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
|
KR20220152220A
(ko)
|
2020-02-12 |
2022-11-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｃｄ19-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도
|
|
EP4103203A1
(en)
|
2020-02-12 |
2022-12-21 |
Juno Therapeutics, Inc. |
Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
|
JP2023522857A
(ja)
|
2020-04-10 |
2023-06-01 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
|
|
AU2021254751B2
(en)
|
2020-04-15 |
2025-01-30 |
Theradaptive, Inc. |
Compositions and methods for targeted therapeutic delivery to bone
|
|
EP4142723A2
(en)
|
2020-04-28 |
2023-03-08 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
CN115803824A
(zh)
|
2020-05-13 |
2023-03-14 |
朱诺治疗学股份有限公司 |
鉴定与临床反应相关的特征的方法及其用途
|
|
US20230181641A1
(en)
|
2020-05-13 |
2023-06-15 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
CN116490518A
(zh)
|
2020-07-17 |
2023-07-25 |
西穆尔克斯股份有限公司 |
用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
|
|
CN116096864A
(zh)
|
2020-07-30 |
2023-05-09 |
居里研究所 |
Socs1缺陷的免疫细胞
|
|
KR20230095918A
(ko)
|
2020-08-05 |
2023-06-29 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
|
|
EP4204447A1
(en)
|
2020-08-28 |
2023-07-05 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
EP4225382A4
(en)
|
2020-10-07 |
2025-04-23 |
AskBio Inc. |
ADMINISTRATION OF THERAPEUTIC ADENO-ASSOCIATED VIRUS FUKKUTIN-ASSOCIATED PROTEIN (FKRP) FOR THE TREATMENT OF DYSTROGLYCANOPATHY. DISORDERS INCLUDING LIMB GIRDLE 21
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
EP4274901A1
(en)
|
2021-01-11 |
2023-11-15 |
Sana Biotechnology, Inc. |
Use of cd8-targeted viral vectors
|
|
EP4301755A1
(en)
|
2021-03-03 |
2024-01-10 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
EP4314814A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
BR112023020012A2
(pt)
|
2021-03-29 |
2023-11-14 |
Juno Therapeutics Inc |
Combinação de uma terapia de células t que expressam car e um composto imunomodulador para o tratamento de linfoma
|
|
CN118201618A
(zh)
|
2021-04-16 |
2024-06-14 |
细胞基因公司 |
与bcma定向t细胞疗法的组合疗法
|
|
EP4334341A2
(en)
|
2021-05-06 |
2024-03-13 |
Juno Therapeutics GmbH |
Methods for stimulating and transducing t cells
|
|
US20250304915A1
(en)
|
2021-05-25 |
2025-10-02 |
Institut Curie |
Myeloid Cells Overexpressing BCL2
|
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
US20240252684A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
JP2024528981A
(ja)
|
2021-08-04 |
2024-08-01 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ４標的化ウイルスベクターの使用
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
JP2025501272A
(ja)
|
2021-12-28 |
2025-01-17 |
ムネモ・セラピューティクス |
不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
EP4463549A2
(en)
|
2022-01-14 |
2024-11-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
KR20240150790A
(ko)
|
2022-02-22 |
2024-10-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
프로테이나제 3 (pr3) 키메라 자가항체 수용체 t 세포 및 관련 방법 및 용도
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
EP4508073A1
(en)
|
2022-04-14 |
2025-02-19 |
Board of Regents of the University of Nebraska |
Cell therapy for alzheimer's disease
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
KR20250029137A
(ko)
|
2022-06-22 |
2025-03-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법
|
|
JP2025524469A
(ja)
|
2022-06-24 |
2025-07-30 |
チューン セラピューティクス インコーポレイテッド |
標的を定めた遺伝子抑制を介して低密度リポタンパク質を低減するための組成物、系、及び方法
|
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
KR20250047766A
(ko)
|
2022-08-05 |
2025-04-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
|
|
AU2023325407A1
(en)
|
2022-08-19 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
JP2025529903A
(ja)
|
2022-08-26 |
2025-09-09 |
ジュノー セラピューティクス インコーポレイテッド |
デルタ様リガンド３（ｄｌｌ３）に特異的な抗体およびキメラ抗原受容体
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
EP4590821A2
(en)
|
2022-09-19 |
2025-07-30 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
EP4611798A1
(en)
|
2022-11-02 |
2025-09-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
CN121100267A
(zh)
|
2022-12-09 |
2025-12-09 |
朱诺治疗学股份有限公司 |
使用全息成像预测细胞表型的机器学习方法
|
|
CN120712102A
(zh)
|
2022-12-13 |
2025-09-26 |
朱诺治疗学股份有限公司 |
对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
CN121127253A
(zh)
|
2023-02-28 |
2025-12-12 |
朱诺治疗学股份有限公司 |
治疗系统性自身免疫性疾病的细胞疗法
|
|
WO2024220588A1
(en)
|
2023-04-18 |
2024-10-24 |
Juno Therapeutics, Inc. |
Cytotoxicity assay for assessing potency of therapeutic cell compositions
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025059362A1
(en)
|
2023-09-13 |
2025-03-20 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025076472A1
(en)
|
2023-10-06 |
2025-04-10 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|